Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Unresectable Hepatocellular Carcinoma Market By 2029?
The market size for unresectable hepatocellular carcinoma has displayed marginal growth in recent years. It is anticipated to expand from $1.98 billion in 2024 to $2.01 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 1.5%. Factors contributing to this historic period’s growth include chemotherapy advances, clinical trial outcomes, liver transplantation limitations, increased cancer cases, and expanded access to therapies.
The market for unresectable hepatocellular carcinoma is projected to experience substantial expansion in the coming years. This market is set to reach $2.93 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.9%. The projected growth during this period stems from factors such as healthcare policy adjustments, patient stratification strategies, the application of real-world evidence, increased patient advocacy and awareness, along with economic and dynamic influences. Key developments anticipated in the forecast period encompass precision medicine and biomarkers, the integration of real-world evidence and data, multidisciplinary treatment strategies, worldwide clinical trials and partnerships, and a focus on patient-centric care.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12079&type=smp
Which Drivers Are Impacting The Unresectable Hepatocellular Carcinoma Market?
The rising incidence of liver cancer is a key factor propelling the expansion of the unresectable hepatocellular carcinoma market. This condition occurs when healthy, functional liver cells are overcome by tumor cells that begin to develop uncontrollably. Unresectable hepatocellular carcinoma is a type of cancer for which treatments include liver transplantation and radiofrequency ablation. Specifically, a report from the Journal of Hepatology in October 2022, a Switzerland-based peer-reviewed scientific journal, stated that globally, 830,200 people had died from liver cancer by 2020. Furthermore, projections indicate that 1.4 million new cases of liver cancer will likely be diagnosed between 2020 and 2040, marking a 55.0% increase in the yearly number of new cases. Additionally, according to the American Cancer Society, a US-based non-profit organization, in January 2024, an estimated 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer are expected to be diagnosed in the U.S. in 2024 (28,000 in men and 13,630 in women). Concurrently, approximately 29,840 deaths are projected (19,120 men and 10,720 women). These statistics confirm that the growing prevalence of liver cancer significantly contributes to the growth of the unresectable hepatocellular carcinoma market.
Which Key Segments Fueling The Unresectable Hepatocellular Carcinoma Market?
The unresectable hepatocellular carcinomamarket covered in this report is segmented –
1) By Type: Primary; Secondary; Benign Liver Growth
2) By Treatment Type: Chemotherapy; Molecularly Targeted Therapy; Immunotherapy; Other Treatments
3) By End-Users: Hospitals; Specialty Clinics; Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC); Fibrolamellar Carcinoma; Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer; Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma; Focal Nodular Hyperplasia; Hemangiomas
Which Key Trends Are Expected To Influence The Unresectable Hepatocellular Carcinoma Market In The Coming Years?
Product innovations are a significant trend gaining momentum in the unresectable hepatocellular carcinoma market. Major companies operating in the unresectable hepatocellular carcinoma market are implementing innovative products to secure their market position. For instance, in October 2022, AstraZeneca, a UK-based pharmaceutical and biotechnology company, launched FDA-approved Imjudo (tremelimumab) in conjunction with Imfinzi in the US for patients with unresectable liver cancer. The new treatment, known as the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), involves a single dosage of the anti-CTLA-4 antibody Imjudo 300mg combined with the anti-PD-L1 antibody Imfinzi 1500 mg administered every four weeks. Patients who received Imjudo and Imfinzi together demonstrated a 22% lower likelihood of mortality compared to those treated with sorafenib.
Which Global Market Leaders Are Shaping The Future Of The Unresectable Hepatocellular Carcinoma Sector?
Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.
Download The Full Report For Exclusive Market Findings:
How Does The Unresectable Hepatocellular Carcinoma Market Perform Across Key Geographic Regions?
North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Unresectable Hepatocellular Carcinoma Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12079&type=smp
Browse Through More Reports Similar to the Global Unresectable Hepatocellular Carcinoma Market 2025, By The Business Research Company
Pain Management Devices And Therapies Global Market Report 2025
Metabolomics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report
Isothermal Nucleic Acid Amplification Technology Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model